Original title: Biopharmaceutical companies seek internationalization of traditional pharmaceutical companies to accelerate their transformation and transformation
Our reporter Zhang Min
In 2021, the China International Trade in Services Fair (hereinafter referred to as the “Service Trade Fair”) set up a health service topic for the first time, which is divided into six themes of epidemic prevention and control, medical services, technological innovation, traditional medicine, elderly health, and international medical care, covering Innovative drugs, high-end medical devices, commercial medical insurance, medical health services, traditional medicine and other fields have become a large stage for domestic and foreign medical device companies to display their strengths and innovative projects.
“The Service Trade Fair is an important window for China to open up to the outside world. It provides an international platform for multinational companies including Bayer to display, communicate, and cooperate. It is also an important way to gain a deeper understanding of China’s local medical needs.” Bayer Group’s prescription drug business Said Zhou Xiaolan, executive vice president of the department and president of China.
It is worth mentioning that the innovation of pharmaceutical devices from China has become the highlight of this service trade fair. The on-site display of the Service Trade Fair and the outstanding performance of business representatives have become the best evidence for the innovation and change of China’s pharmaceutical and biological industry.
Song Ruilin, executive chairman of the China Pharmaceutical Innovation Promotion Association, told a reporter from the Securities Daily: “I hope to use the platform of the Service Trade Association to fully demonstrate China’s innovative drug research and development level and medical service level. I hope that China’s innovative products will not only meet the medical needs of the people in the country. , Through the platform of the Service and Trade Association, to achieve international multilateral and bilateral mutual recognition, so that Chinese medicines and medical devices can go to more countries and contribute to global health.”
Innovative pharmaceutical companies seek international opportunities
At the Service Trade Fair last year, two domestically-made inactivated vaccines for the new crown were unveiled, and the development of China’s health and hygiene industry has attracted worldwide attention. The reporter saw at the venue of the Shougang Park of the Service Trade Fair that more and more innovative pharmaceutical companies appeared at the Service Trade Fair this year compared to 2020. BeiGene, Yasheng Pharmaceutical, Nuocheng Jianhua, and Fu Innovative enterprises such as Honghanlin were displayed on the same stage.
This time, Sinopharm Group China Biotech unveiled 4 new crown vaccines and specific drugs for the treatment of new crown pneumonia; Fuhong Hanli, a subsidiary of Fosun Pharma, brought rituximab injection, trastuzumab for injection, and adalimumab Injections and other appearances. In addition, many companies have announced that they have reached a number of cooperation with the help of this service trade fair. On September 3, the innovative pharmaceutical company Yasheng Pharmaceutical entered into a cooperation with Kangsheng Global Gene Technology Co., Ltd. and Supai Health to prepare for the commercialization of the company’s drugs under research. Nuocheng Jianhua and Connoa signed a strategic cooperation agreement to further deepen the R&D cooperation between the two parties and are committed to the development of First-in-class (first-in-class) macromolecular innovative drugs.
In recent years, with the rapid development of innovative drugs in China, overseas markets have become an important goal for the development of domestic innovative pharmaceutical companies. Innovative pharmaceutical companies such as BeiGene, Rongchang Biotechnology, and Jakesi have promoted innovative products to go overseas through overseas authorization. .
At the scene of the Service Trade Fair, BeiGene President Wu Xiaobin told the reporter of the Securities Daily: “The Service Trade Fair is an important platform for China’s foreign exchanges. We are also very much looking forward to the development opportunities brought by the Service Trade Fair. In the past, developing countries basically Can not afford innovative drugs and patented drugs in the biopharmaceutical field. These drugs are produced by European and American companies at very high prices. Since the rapid development of innovative drugs in China, innovative drugs have been greatly changed, such as cancer drugs that are unattainable. We hope that this situation will not only happen in China, but Chinese pharmaceuticals, especially bio-innovative drugs, should be allowed to go to other developing countries and benefit patients in those countries.”
At present, the original class 1 new drug oribatinib of Ascent Pharmaceuticals for the treatment of patients with drug-resistant chronic myeloid leukemia (CML) has submitted a new drug marketing application in China and is simultaneously conducting clinical trials in the United States. According to Yang Dajun, Chairman and CEO of Yasheng Pharmaceutical, after the product is approved for listing in the future, it will be fully commercialized in the European and American markets, the “Belt and Road” market, and emerging markets.
“Chinese innovative pharmaceutical companies must have a global vision, a global voice, and a global pricing power. This is also the goal we pursue in the future. Chinese biomedicine, especially innovative drugs, can go to the world. A big country and a strong country are very meaningful.” Yang Dajun said.
Traditional pharmaceutical companies accelerate change
In the 2021 government work report, it was proposed that “adhering to the equal emphasis on Chinese and Western medicine and implementing the major project for the revitalization and development of Chinese medicine”, and the historical status of Chinese medicine has been greatly improved. At present, the Chinese medicine industry is in a “golden period” of development.
Leading enterprises such as Beijing Tongrentang, China Resources Sanjiu and Baiyunshan also participated in the Fair. The reporter saw at the scene that, on the one hand, the inheritance of traditional Chinese medicine was shown: at the Beijing Tongrentang booth, the staff demonstrated the production methods of traditional Chinese medicine on the spot, which attracted many audiences to watch. On the other hand, traditional Chinese medicine is accelerating the integration of science and technology. The remote diagnosis and treatment platform of Chinese medicine, meridian conditioning robots, moxibustion smart devices and other technologically full products are very eye-catching.
Under the background that the country encourages innovation, the transformation and development of traditional pharmaceutical companies has aroused the attention of the capital market, and reporters have also seen this change on the spot.
Medical beauty is a hot spot in the capital market in 2021, and hair loss is a hotter branch. The reporter saw at the exhibition hall that the traditional Chinese medicine company Zhendong Group adopted Chinese traditional style design, and displayed the company’s Wuhe Yiyangtang products, Da Feixin, Zhendong Kanghu, Langdi calcium and Chinese herbal medicine in different areas. Among them, Faixin, as the company’s hair growth medical beauty product, attracted the attention of visitors.
In the exhibition hall of Dafeixin Hair Development Service Center, Zhendong Group placed a professional hair follicle detector for the visitors to experience the detection of scientific instruments on site. The reporter learned from the staff at the scene that in the future, Zhendong Group will take the field of medical beauty and hair loss as an important development direction, and increase investment in innovative drugs, focus on the field of oncology, and become a long-term innovative enterprise.
In addition, the reporter saw the facial mask products produced by an injection manufacturer at the platform of an injection manufacturer, which is a common choice for companies to enter the medical beauty track. The staff of the company introduced to a reporter from the Securities Daily that this time the product was only used as a display, without large-scale publicity, most of which were for internal use by the company.
.